InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2024
May 07, 2024 16:05 ET
|
InnovAge
INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL THIRD QUARTER ENDED MARCH 31, 2024
EverQuote to Participate in Upcoming Investor Conferences
May 07, 2024 16:05 ET
|
EverQuote, Inc.
CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, today announced that management will present or host one-on-one investor...
ClearPoint Neuro Reports First Quarter 2024 Results
May 07, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
Q1-2024 Revenue Growth +41%, a Company Record
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
May 07, 2024 16:05 ET
|
Y-mAbs Therapeutics, Inc.
Reported U.S. DANYELZA® net product revenues of $18.6 million for the first quarter of 2024, representing a YoY increase of 11% Reported Worldwide DANYELZA net product revenues of $19.4 million for...
Comscore Reports First Quarter 2024 Results
May 07, 2024 16:05 ET
|
Comscore, Inc.
RESTON, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Comscore, Inc. (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media across platforms, today reported financial results for...
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
May 07, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing...
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 07, 2024 16:05 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers...
ODDITY Tech Reports Record First Quarter Results, Raises Outlook
May 07, 2024 16:05 ET
|
Oddity Tech Ltd.
Record first quarter net revenue of $212 million, up 28% year-over-yearRecord first quarter net income of $33 million, up 68% year-over-year, and record first quarter adjusted net income of $38...
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
May 07, 2024 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., May 07, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
Oculis Publishes Invitation to the Annual General Meeting
May 07, 2024 16:05 ET
|
Oculis Holding AG
Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on...